

Gangliosides of Human Erythrocytes. A Novel Ganglioside with a Unique *N*-Acetylneuraminosyl-(2→3)-*N*-acetylgalactosamine Structure[†]

Kiyohiro Watanabe[†] and Sen-itiroh Hakomori*

ABSTRACT: A novel ganglioside having both *N*-acetylgalactosamine and *N*-acetylglucosamine was isolated from human erythrocyte membranes. Its structure was characterized by successive exoglycosidase treatment, methylation analysis, and direct-probe mass spectrometry of permethylated intact and desialylated glycolipid. The core structure of the

ganglioside was found to be *N*-acetylgalactosaminyl paragloboside with sialosyl substitution by 2→3 linkage at the terminal GalNAc residue: NeuNAcα2→3GalNAcβ1→3Galβ1→4GlcNAcβ1→3Galβ1→4Glc→Cer. The ganglioside was characterized by the presence of a ceramide with myristic acid as the major component.

Our recent studies on gangliosides of human erythrocyte membranes established the presence of nine monosialosyl gangliosides (G₁–G₉). These are hematoside (G₁), two sialosyl paraglobosides having sialosyl2→3Gal (G₂) and sialosyl2→6Gal (G₄), two sialosyllacto-*N*-norhexaosylceramides having sialosyl2→3Gal (G₆) and sialosyl2→6Gal (G₇), GM_{1b} ganglioside (G₅), and those having a branching structure with blood group I and H activities (G₈ and G₉) (Watanabe et al., 1978, 1979). One ganglioside, previously isolated and designated as G₃, has now been identified as having both *N*-acetylgalactosamine and *N*-acetylglucosamine. This ganglioside, characterized by a novel sialosyl2→3GalNAc structure, is described in this paper.

Materials and Methods

The monosialosyl gangliosides were isolated and purified from human type O erythrocyte membranes according to the methods as previously described (Watanabe et al., 1978, 1979). The gangliosides from the Folch's upper phase (Folch-Pi et al., 1951) were separated from neutral glycolipids by chromatography on DEAE-Sephadex A-25 (Yu & Ledeen, 1972). The monosialosyl gangliosides were separated into components by chromatography on silicic acid (Bio-Sil-A, Bio Rad Laboratories, CA), followed by preparative TLC¹ on silica gel H according to the methods previously described (Watanabe et al., 1978, 1979). The structure of purified ganglioside G₃ was determined by degradation with exoglycosidases (Hakomori et al., 1971), methylation analysis (Hakomori, 1964; Björndal et al., 1970; Stellner et al., 1973), and direct-probe mass spectrometry of permethylated glycolipid (Karlsson et al., 1974; Ledeen et al., 1974; Watanabe et al., 1975) before and after desialylation as previously described (Watanabe et al., 1979).

Results

The carbohydrate composition of the ganglioside was found to be quite unique; it contained both glucosamine and galac-

Table I: Migration Rate of Enzymatic Products from Ganglioside G₃

| enzyme | R _{pg} value ^a |
|--|------------------------------------|
| intact G ₃ | 0.08 |
| sialidase | 0.35 |
| β- <i>N</i> -acetylhexosaminidase | 0.96 |
| β-galactosidase | 1.50 |
| β- <i>N</i> -acetylglucosaminidase | 1.99 |
| ganglio- <i>N</i> -tetraosylceramide (asialo-GM ₁) | 0.51 |
| lacto- <i>N</i> -neotetraosylceramide | 1.00 |
| lacto- <i>N</i> -triosylceramide | 1.51 |
| lactosylceramide | 1.89, 2.04 ^b |

^a Rate of paragloboside is defined as 1.00, determined on a silica gel G plate developed with chloroform-methanol-water (65:25:4 v/v). ^b Double spots due to the difference in ceramide.

tosamine. The molar ratio of Gal/Glc/GlcNAc/GalNAc/NeuNAc/sphingosine was found to be 2.2:1.0:0.8:0.7:0.9:0.7. The purified ganglioside G₃ showed the same R_{pg} value as brain GM₁ ganglioside (0.75 for G₃ and 0.72 for GM₁). However, the sialosyl residue of G₃ was readily hydrolyzed by sialidase. The desialylated core glycolipid, produced by sialidase or weak acid hydrolysis, migrated slower than asialo-GM₁ (R_{pg} value was 0.35 for asialo-G₃ and 0.51 for asialo-GM₁) (Table I). The asialo-G₃ was then hydrolyzed by jack bean β-*N*-acetylhexosaminidase and was converted to a compound having a similar mobility on TLC (R_{pg} = 0.96) as paragloboside. The paragloboside-like product was further degraded by jack bean β-galactosidase and was converted to a ceramide trisaccharide having a terminal *N*-acetylglucosamine (lacto-*N*-triosylceramide GlcNAcβ1→3Galβ1→4Glc→Cer). This glycolipid was degraded by beef kidney β-*N*-acetylglucosaminidase (Boehringer Mannheim Biochemicals, IN) to a lactosylceramide.

The sequence of carbohydrate was further confirmed by direct-probe mass spectrometry of the permethylated intact glycolipid and that of the permethylated desialylated compound (see parts A and B of Figure 1). The ions *m/e* 376 and 344 (376 – 32) assigned for *N*-acetylneuraminic acid were detected as a nonreducing terminal sugar from a permethylated intact ganglioside. Detection of the ions *m/e* 621 and 589 (621 – 32) indicated the presence of NeuNAc–HexNAc structure as a nonreducing terminal disaccharide residue,² and the ions

[†] From the Program of Biochemical Oncology, Fred Hutchinson Cancer Research Center, Departments of Pathobiology, Microbiology, and Immunology, School of Public Health and School of Medicine, University of Washington, Seattle, Washington 98104. Received June 11, 1979. This investigation has been supported by research grants from the National Institutes of Health (CA19224 and CA20026). This is the third report from this laboratory dealing with gangliosides of human erythrocytes [see Watanabe et al. (1978, 1979) for the first and second papers in this series].

* Present address: The Shigei Medical Research Institute, Okayama, Japan.

¹ Abbreviations used: TLC, thin-layer chromatography; R_{pg} value, rate of TLC mobility as compared to that of sialosyl paragloboside as 1.00; R_{pg}, rate of TLC mobility as compared to that of paragloboside as 1.00.





FIGURE 1: Mass spectra and simplified formula for interpretation of the fragment ions derived from permethylated intact and desialylated ganglioside G₃. Panel A: mass spectrum of permethylated intact ganglioside. Panel B: after desialylation. Mass spectrometry was performed with a Finnigan 3300 mass spectrometer with 6110 data system under the following conditions: electron energy, 30 V; ion energy programmed from +3.5 V; extractor, +8.0 V; lens, 35 V; emission, 0.5 mA; electron multiplier, 2220 V; sensitivity, 10^{-7} A/V. Ordinate, relative intensity (percent); abscissa, m/e . Panel C: simplified formula for interpretation of the fragment ions derived from carbohydrate moieties of permethylated intact and desialylated ganglioside. NeuNAc, *N*-acetylneuraminic acid; Hex, hexose; HexNAc, hexosamine; Cer, ceramide.

m/e 825 and 793 ($825 - 32$) are assigned to the terminal trisaccharide as NeuNAc-HexNAc-Hex. These ions are very unique for this glycolipid and have never been detected in other gangliosides. In addition to the ions m/e 450 and 418 ($450 - 32$), the ions for the internal disaccharide HexNAc-Hex or Hex-HexNAc, m/e 695 ($694 + 1$) and 663 ($695 - 32$), were detected, which were assigned to the internal trisaccharide HexNAc-Hex-HexNAc. The detection of these ions clearly indicated the presence of two hexosamines in one molecule.

² The permethylated intact G₃ gave an ion m/e 260 on direct-probe mass spectrometry. This ion has been assigned and regarded as the diagnostic value for the nonreducing terminal hexosamine (Karlsson et al., 1974; Ledeen et al., 1974; Watanabe et al., 1975). Obviously, an intact G₃ had no terminal hexosamine as judged on methylation analysis. The presence of m/e 260 in the direct-probe mass spectrometry is difficult to explain. It may be that NeuNAc \rightarrow 3GalNAc may be cleaved and the sialic acid linked GalNAc could be converted to a structure as shown below (left) which has m/e 260 ($259 + 1$). The origin of m/e 246 and 214 ($246 - 32$) could be as shown below (center and right).



From the desialylated glycolipid, on the other hand, ions representing the nonreducing terminal hexosamine (m/e 260 and 228) were detected in addition to the ions m/e 464, 432 (HexNAc-Hex), 709, 677 (HexNAc-Hex-HexNAc), 913, and 881 (HexNAc-Hex-HexNAc-Hex). Thus, the ganglioside G₃ should have the carbohydrate sequence as follows: NeuNAc-HexNAc-Hex-HexNAc-Hex-Hex-Cer.

The results of the methylation analysis gave details of the carbohydrate linkages. As shown in Figure 2, the intact ganglioside, after methylation and hydrolysis, gave both 3,6-di-*O*-methyl-2-(*N*-methylacetamido)glucitol and 4,6-di-*O*-methyl-2-(*N*-methylacetamido)galactitol, in addition to 2,4,6-tri-*O*-methylgalactitol and 2,3,6-tri-*O*-methylglucitol. Desialylated ganglioside (asialo-G₃) gave, on methylation and hydrolysis, 3,4,6-tri-*O*-methyl-2-(*N*-methylacetamido)galactitol but did not give 4,6-di-*O*-methyl-2-(*N*-methylacetamido)-2-deoxygalactitol (Figure 2B). It also gave 2,4,6-tri-*O*-methylgalactitol and 2,3,6-tri-*O*-methylglucitol. No tetra-*O*-methylhexitol was detected in the hydrolysate of permethylated desialylated G₃ ganglioside. These data clearly indicated that sialosyl substitution is at the GalNAc residue with a 2 \rightarrow 3 linkage.

The ganglioside failed to react with the following antibodies by double-diffusion precipitation on agarose gel plate with anti-brain GM₁, anti-asialo-GM₁, anti-asialo-GM₂, anti-Forssman glycolipid, and antigloboside antibodies. The ganglioside after removal of sialic acid reacted weakly with anti-




FIGURE 2: Mass fragmentogram for hexosamine (ion m/e 158) of the hydrolysate of permethylated intact and desialylated ganglioside. Panel A: intact ganglioside. Panel B: after desialylation. Panel C: Forssman glycolipid as the standard compound. Panel D: paragloboside as the standard compound. Identified peaks are (1) 3,6-di-*O*-methyl-2-(*N*-methylacetamido)glucitol 1,4,5-tri-*O*-acetate, (2) 4,6-di-*O*-methyl-2-(*N*-methylacetamido)galactitol 1,3,5-tri-*O*-acetate, and (3) 3,4,6-tri-*O*-methyl-2-(*N*-methylacetamido)galactitol 1,5-di-*O*-acetate, determined with a Finnigan 3300 mass spectrometer with 6110 data system. The permethylated sample, isolated and purified on Sephadex LH-20 column (Pharmacia Chemicals), was hydrolyzed in 90% acetic acid–0.5 N H_2SO_4 for 5 h under a nitrogen atmosphere. The partially *O*-methylated amino sugars in the hydrolysate were reduced and acetylated by the procedure previously described (Stellner et al., 1973). The entire modified procedure was recently described (Watanabe et al., 1978, 1979). Gas chromatography was performed on a 5 ft \times 2 mm column of 3% OV-17 coated on Spectoport 80–100 mesh at 190 °C isothermal. Conditions of mass spectrometry: electron energy, 70 V; ion energy, 3.0 V; electron multiplier, 1800 V; sensitivity, 10^{-7} A/V. Ordinate, ion intensity; abscissa, scan number.

asialo-GM₂ and antigloboside antibody, respectively. This reactivity must be a cross reaction between the structures having a terminal β -GalNAc, indicating that the nonreducing terminal hexosamine of asialo G₃ should be β -*N*-acetyl-galactosamine. On the basis of the above data, the chemical structure of ganglioside G₃ is proposed to be NeuNAc α 2 \rightarrow 3GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc \rightarrow Cer. This ganglioside is characterized by the presence of a large proportion of myristic acid (Table II), and the sphingosine base was C₁₈ sphinganine.

Table II: Fatty Acid Composition of Ganglioside G₃^a

| | % | | % |
|--------------|------|--------------|------|
| 12:0 | 0.3 | unidentified | 1.2 |
| 13:0 | 0.6 | 19:0 | 2.2 |
| 14:0 | 37.8 | 20:0 | 6.1 |
| 14:1 | 0.9 | 20:1 | 8.8 |
| 15:0 | 0.4 | 21:0 | 0.7 |
| 15:1 | 0.8 | 21:1 | 0.6 |
| 16:0 | 6.9 | 22:0 | 10.8 |
| 16:1 | 3.7 | 22:1 | 11.7 |
| unidentified | 0.6 | 24:0 | 1.0 |
| 18:0 | 1.3 | 24:1 | 2.4 |
| 18:1 | 1.2 | | |

^a Analyzed by gas chromatography on 3% ethyl-30 column after methanolysis according to the method of Gaver & Sweeley (1965).

Discussion

The results clearly indicate the unique structure of this ganglioside, containing (1) both *N*-acetylglucosamine and *N*-acetylglucosamine and (2) a sialosyl2 \rightarrow 3GalNAc structure. In all gangliosides hitherto isolated, the sialosyl residue was linked to the galactosyl residue of ganglio-*N*-tetraosylceramide or lacto-*N*-neotetraosylceramide or their analogues, and the linkage has been limited to α 2 \rightarrow 3Gal. An exception has been described which has sialosyl2 \rightarrow 6Gal (Wiegandt, 1973; Watanabe et al., 1979). Ganglioside G₃ is now identified as having a unique sialosyl linkage, sialosyl-(2 \rightarrow 3)-*N*-acetylglucosamine. The ganglioside is a minor component of erythrocyte membranes, but a carbohydrate chain with the same sequence may be present in the glycoprotein. Kóscielak et al. (1978) reported that glycolipids with short fatty acid aliphatic chains may be serum-derived. Because this ganglioside also has a large amount of C₁₄ fatty acid (myristic acid), it may be interesting to see if the same ganglioside is present in a larger quantity in serum.

References

- Björndal, H., Hellerqvist, C. G., Lindberg, B., & Svensson, S. (1970) *Angew. Chem., Int. Ed. Engl.* 9, 610–619.
- Folch-Pi, J., Arsove, S., & Meath, J. A. (1951) *J. Biol. Chem.* 191, 819–831.
- Gaver, R. C., & Sweeley, C. C. (1965) *J. Am. Oil Chem. Soc.* 42, 294–298.
- Hakomori, S. (1964) *J. Biochem. (Tokyo)* 55, 205–208.
- Hakomori, S., Siddiqui, B., Li, Y.-T., Li, S.-C., & Hellerqvist, C. G. (1971) *J. Biol. Chem.* 246, 2271–2277.
- Karlsson, K.-A., Pascher, I., Pimlott, W., & Samuelsson, B. E. (1974) *Biomed. Mass Spectrom.* 1, 49–56.
- Kóscielak, J., Maślinski, W., Zieleński, J., Zdebska, E., Brudzyński, T., Miller-Podraza, H., & Cedergren, H. (1978) *Biochim. Biophys. Acta* 530, 385–393.
- Ledeer, R. W., Kundu, F. K., Price, H. C., & Fong, J. W. (1974) *Chem. Phys. Lipids* 13, 429–446.
- Stellner, K., Saito, H., & Hakomori, S. (1973) *Arch. Biochem. Biophys.* 155, 464–472.
- Watanabe, K., Laine, R. A., & Hakomori, S. (1975) *Biochemistry* 14, 2151–2156.
- Watanabe, K., Powell, M. E., & Hakomori, S. (1978) *J. Biol. Chem.* 253, 8962–8967.
- Watanabe, K., Powell, M. E., & Hakomori, S. (1979) *J. Biol. Chem.* 254, 8223–8229.
- Wiegandt, H. (1973) *Hoppe-Seyler's Z. Physiol. Chem.* 354, 1049–1056.
- Yu, R. K., & Ledeen, R. W. (1972) *J. Lipid Res.* 13, 680–686.